Renascience

Renascience CapEx/OCF

CapEx to Operating Cash Flow Ratio of Renascience (4889.T) as of Nov 19, 2026.

CapEx/OCF

0.00

Last updated:

CapEx to Operating Cash Flow Ratio of Renascience is 2026 0.00 . CapEx to Operating Cash Flow Ratio of Renascience was 2025 -0.45 % . It decreases by % higher compared to the previous year.

The Renascience CapEx/OCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

CapEx/OCF
Date
CapEx/OCF
Jan 1, 2020
0.00 JPY
Jan 1, 2021
-1.13 JPY
Jan 1, 2022
-0.51 JPY
Jan 1, 2023
-0.78 JPY
Jan 1, 2024
-0.68 JPY
Jan 1, 2025
-0.45 JPY
Jan 1, 2026
0.00 JPY
The Renascience CapEx/OCF history
YEARCapEx/OCFYoY
0.00-100.00%
-0.45 %-33.77%
-0.68 %-12.48%
-0.78 %+54.79%
-0.51 %-55.37%
-1.13 %—
0.00—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Renascience Stock analysis

What does Renascience do? Renascience, Inc. develops and sells pharmaceuticals, focusing on drugs for four non-infectious aging-related diseases: cancer, diabetes, respiratory diseases, and cardiovascular diseases. The company collaborates with physicians in research and development of pharmaceuticals, medical devices, and AI solutions for medical problems. Its products target aging-related health issues, including women's and children's diseases and solutions for COVID-19 infection. The firm's revenue comes from the sale of developed pharmaceuticals, medical devices, and AI solutions. Physicians and medical institutions are key buyers of its products, as the company's R&D is conducted in collaboration with them. The primary market segments are aging populations suffering from chronic conditions and healthcare providers seeking innovative medical solutions. Renascience, Inc. operates with a small team of three full-time employees, emphasizing focused R&D on specific medical challenges. Its business model centers on developing targeted therapies for high-impact diseases, leveraging partnerships with physicians to address unmet medical needs in aging-related health conditions. Renascience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Renascience stock

On Eulerpool you can find the complete historical development of CapEx to Operating Cash Flow Ratio Renascience since 2006 – with annual values, charts, and detailed analysis.

The CapEx/OCF ratio shows what percentage of operating cash flow is reinvested in capital assets. Lower ratios indicate more free cash available for shareholders.

A 'good' varies by industry and company stage. On Eulerpool, you can compare CapEx to Operating Cash Flow Ratio's Renascience with sector peers and the industry average to assess whether it is attractive.

To evaluate CapEx to Operating Cash Flow Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for CapEx to Operating Cash Flow Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Renascience

All Key Metrics — Renascience